Wegovy 7.2mg: The Strongest Semaglutide Dose Now Available in the UK

If you have been using Wegovy for weight management and your progress has slowed, or you are curious about whether a stronger dose could make a meaningful difference, you are not alone. Wegovy 7.2mg the highest licensed dose of semaglutide available in the UK is now changing what is possible for adults living with obesity.

At Holroyd Pharmacy, we supply the full range of Wegovy pre-filled pens, including the 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg, and 7.2mg strengths, as part of our commitment to providing genuine UK medicines with professional clinical support. This guide covers everything you need to know about the 7.2mg dose in plain, honest terms.

What Is Wegovy 7.2mg?

Wegovy 7.2mg is the highest available dose of semaglutide, the active ingredient in Wegovy. It works in the same way as all other Wegovy strengths by mimicking a natural gut hormone called GLP-1 (glucagon-like peptide-1). This hormone signals to your brain that you are full, slows the rate at which food leaves your stomach, and reduces appetite and cravings.

The 7.2mg dose is simply three times stronger than the previous maximum dose of 2.4mg. It was developed specifically for patients who have been stable on the 2.4mg dose but need additional support to continue losing weight or have hit a plateau.

The Medicines and Healthcare products Regulatory Agency (MHRA) approved the 7.2mg dose on 6 January 2026, making it the strongest semaglutide option available for weight management in the United Kingdom. Initially, it was administered as three separate 2.4mg injections taken in the same sitting. As of 14 April 2026, the MHRA approved a new single-dose 7.2mg pre-filled pen, meaning patients now receive their full weekly dose in one convenient injection.

What Do Clinical Trials Show?

The evidence behind Wegovy 7.2mg is compelling and comes from the STEP UP trial a phase 3b randomised controlled study published in The Lancet Diabetes & Endocrinology. The results were significant:

• Patients on the 7.2mg dose lost an average of 20.7% of their body weight over 72 weeks
• This compared to 17.5% body weight loss achieved on the standard 2.4mg dose
• Notably, 33.2% of patients on the higher dose lost 25% or more of their starting body weight a threshold previously associated only with bariatric surgery or the maximum dose of Mounjaro (tirzepatide 15mg)

These figures are meaningful. For someone weighing 110kg, a 20.7% reduction equates to more than 22kg of weight loss. For many patients, that kind of result can have a transformative impact on cardiovascular health, joint pain, blood pressure, blood sugar management, and overall quality of life.

The STEP UP trial also found the 7.2mg dose retained a favourable risk-benefit profile, meaning its safety was consistent with what patients and clinicians already expect from semaglutide though side effects were somewhat more frequent at the higher dose.

Who Is Eligible for Wegovy 7.2mg?

The 7.2mg dose is not suitable for everyone. Here is what you need to know about eligibility.

You must already be on Wegovy 2.4mg. You cannot start directly on 7.2mg. The standard Wegovy dose escalation schedule starts at 0.25mg per week and increases every four weeks until reaching 2.4mg. You must have been on the 2.4mg dose for at least four weeks before a prescriber will consider moving you up to 7.2mg.

The MHRA has restricted 7.2mg to patients with obesity (BMI of 30 or above). Unlike the lower doses, which can be prescribed for adults with a BMI of 27 or above alongside a weight-related condition, the 7.2mg dose is specifically approved only for patients with a BMI of 30kg/m² or higher. It does not apply to those using Wegovy to reduce cardiovascular risk without a full obesity diagnosis.

You should have minimal or no side effects on 2.4mg. The 7.2mg dose is intended for patients who tolerate 2.4mg well and still require further weight loss support, not for those who struggled with nausea, vomiting, or other side effects at the standard maintenance dose.

It is not necessary to escalate. If you are achieving satisfactory results and feel well on 2.4mg, there is no clinical requirement to move up. The higher dose exists for those who need it not as a default progression for all patients.

If you are unsure whether 7.2mg is appropriate for you, our team at Holroyd Pharmacy can provide guidance and work with your prescribing clinician to assess your suitability.

How Is Wegovy 7.2mg Administered?

Since 1 June 2026, Wegovy 7.2mg has been available in the UK as a single-dose pre-filled pen meaning one injection per week delivers the full 7.2mg dose. This is a significant improvement in convenience compared to the earlier three-pen approach.

Here is what to expect when using the single-dose pen:

• The pen arrives refrigerated and must be stored between 2°C and 8°C until use
• Unlike multi-dose pens used for lower Wegovy strengths, the 7.2mg single-dose pen contains just one dose and is disposed of after use
• The pen comes with the needle already attached, so you do not need to apply one before injecting or remove it afterwards
• Before injecting, check the pen is not damaged or expired and that the solution through the window appears clear and colourless
• Choose your injection site the stomach, thigh, or upper arm are all suitable and rotate sites regularly to avoid skin reactions
• Press the pen firmly against your skin and administer the dose as instructed by your prescriber or pharmacist

Always use Wegovy exactly as directed by your healthcare professional. If you are ever unsure about your injection technique, contact us at Holroyd Pharmacy and we will be happy to walk you through it.

What Are the Side Effects of Wegovy 7.2mg?

Side effects with Wegovy 7.2mg are broadly the same as those seen with other doses, but they are generally more frequent at this higher strength. The most common side effects are gastrointestinal in nature.

Common side effects include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Stomach discomfort or bloating
• Reduced appetite (this is also the desired therapeutic effect)

These effects are most pronounced during the dose escalation phase and typically settle as the body adjusts. Gradual titration starting at a low dose and building up slowly exists precisely to help minimise these side effects.

In clinical trials, 3.3% of patients on the 7.2mg dose discontinued treatment due to gastrointestinal side effects, compared to 2.0% on the 2.4mg dose. While this is a small absolute increase, it highlights the importance of being well-established and comfortable on 2.4mg before escalating.

More serious but less common side effects can include pancreatitis, gallbladder problems, and changes in heart rate. Wegovy must not be used during pregnancy, and women should stop treatment at least two months before planned conception.

If you experience any unexpected or severe side effects, contact your prescribing clinician or pharmacist immediately. Side effects can also be reported directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Is Wegovy 7.2mg Available on the NHS?

Currently, Wegovy 7.2mg is not available on the NHS. While the MHRA approval granted the licence for prescribing in the UK, NHS availability requires a separate and additional step a Technology Appraisal by NICE (the National Institute for Health and Care Excellence).

This review process typically takes six to nine months after MHRA approval. NHS access to the 7.2mg dose is therefore unlikely before late 2026 or early 2027 at the earliest. When it does become available on the NHS, eligibility criteria are expected to be stricter than for private prescriptions likely requiring a BMI of 35 or above, and access will probably be through specialist NHS weight management programmes only.

For patients who want to access Wegovy 7.2mg now, private prescriptions through registered UK pharmacies like Holroyd Pharmacy remain the route. Our team ensures all medication comes from official, regulated manufacturers and that treatment is supported by appropriate clinical oversight.

Wegovy 7.2mg vs 2.4mg: Is the Upgrade Worth It?

This is one of the most common questions we receive. The honest answer is: it depends on your individual situation.

If you are losing weight steadily and feeling well on 2.4mg, there is no pressing reason to change. The 2.4mg dose delivers clinically meaningful weight loss for the majority of patients, and staying at the lowest effective dose generally minimises the risk of side effects.

However, if you have been on 2.4mg for several months and your weight loss has stalled or slowed significantly despite following dietary and lifestyle guidance, 7.2mg offers a clinically validated next step. The STEP UP trial data clearly shows the higher dose achieves greater weight reduction, and for patients targeting substantial long-term results, the additional efficacy can be worthwhile.

Your prescriber and pharmacist can help you weigh up the benefits versus the slightly increased risk of side effects to make an informed decision that is right for you.

Wegovy 7.2mg at Holroyd Pharmacy

Holroyd Pharmacy is a GPhC-registered online pharmacy based in Bradford, West Yorkshire. We supply the complete range of Wegovy pre-filled pens, including all dose strengths from 0.25mg through to 7.2mg, with genuine UK medicines sourced from official manufacturers and suppliers.

We pride ourselves on confidential, discreet service with express delivery available across the UK. Our team is available by phone on (01274) 738866 or by email at info@holroydpharmacy.co.uk to answer any questions about your treatment.

Whether you are beginning your weight management journey or considering whether 7.2mg is the right next step, we are here to help you navigate your options with clarity and care.

Frequently Asked Questions

Can I start Wegovy on the 7.2mg dose?

No. The 7.2mg dose is only available to patients who are already established on the 2.4mg dose for a minimum of four weeks with good tolerability.

Do I have to switch to 7.2mg when I reach 2.4mg?

No. Moving to 7.2mg is a clinical decision made between you and your prescriber. If 2.4mg is working well for you, you can remain on it.

How is the 7.2mg pen different from other Wegovy pens?

The 7.2mg single-dose pen (available since June 2026) is a single-use pen containing one dose. Unlike multi-dose pens, it comes with the needle already attached and is discarded after each use.

Will Wegovy 7.2mg ever be on the NHS?

NHS availability is anticipated but not yet confirmed. NICE must complete its appraisal first, which is expected to take until late 2026 or beyond.

Is Wegovy 7.2mg safe?

Clinical trials show the 7.2mg dose retains a favourable safety profile, though side effects particularly gastrointestinal ones are more common than at 2.4mg. It is a prescription-only medication requiring ongoing clinical review.